Excipient-Control Strategies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Excipient-Control Strategies
The authors outline excipient-control strategies and practices for the manufacture, distribution, and receipt of excipients.


Pharmaceutical Technology


Looking forward

By following the measures described in this article, the excipient supply chain can continue to provide excipients that are suitable for use in pharmaceuticals.

Irwin Silverstein*, PhD, is vice-president and chief operating officer, and Arthur Falk, PhD, is president and CEO, both at International Pharmaceutical Excipients Auditing,1655 N. Fort Myer Drive, Suite 700, Arlington, VA 22209, tel. 703.351.5266,
. Dale Carter, MS, is global director of quality of J.M. Huber's silica business unit. Maria Guazzaroni Jacobs, PhD, is director of quality and regulatory policy for worldwide pharmaceutical sciences at Pfizer. David Schoneker is director of global regulatory affairs at Colorcon, chairman of the International Pharmaceutical Excipients Council of the Americas (IPEC–Americas), and a member of Pharmaceutical Technology's Editorial Advisory Board.

*To whom all correspondence should be addressed.

References

1. Code of Federal Regulations, Title 21 Food and Drugs (US Government Printing Office, Washington, DC) Part 110, pp. 216–226.

2. IPEC, "White Paper on Excipient Pedigree," manuscript in progress as of Sept. 3, 2008.

3. IPEC–Americas, Standardized Excipient Information Protocol User Guide (Arlington, VA, 2005).

4. D. Klug, A. Van Meter, and Laura Horne, "The Excipient Information Package, A Win–Win Solution," Pharm. Technol. 31 (11), 121–122 (2007).

5. USP 31–NF 26 General Chapter <1078>, "Good Manufacturing Practices for Excipients."

6. IPEC, The Joint IPEC–PQG Good Manufacturing Practices Guide for Bulk Excipients (2006).

7. IPEC, The Joint IPEC–PQG Good Manufacturing Practices Audit Guide for Pharmaceutical Excipients (2007).

8. IPEC, The IPEC Good Distribution Practices Guide for Pharmaceutical Excipients (2006).

9. IPEC, The IPEC Good Distribution Practices Guide for Pharmaceutical Excipients (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here